● Recruiting

Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma

Condition: Gastric Cancer · Sponsor: Fujian Cancer Hospital

PhasePhase 3

Planned participants269

Who can joinAll sexes, 18 Years to 70 Years

Healthy volunteersNo

About this study

To compare the efficacy and safety of tislelizumab combined with FOLFOX or combined with POF in the treatment of locally advanced unresectable or metastatic gastric/gastroesophageal junction adenocarcinoma with CPS≥1

This description comes directly from the study's public registry record.

Talk to the study team

Rong bo Lin, bachelor · 13705919382 · rongbo_lin@163.com

Always discuss trial participation with your own doctor first.

Locations (1)

Fujian cancer hospital

Fuzhou, Fujian, China

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06793917